Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 9/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | AKT2 | P31751 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27207460 | 1.00 | STING1 (0.41) | STING1ADORA2AKMT2AAKT1AKT2 | |
| SCHEMBL21620360 | 0.89 | STING1 (0.42) | STING1ADORA2AKMT2A | |
| Bromide SCHEMBL21616426 | 0.88 | STING1 (0.41) | STING1ADORA2AKMT2A | |
| SCHEMBL21620363 | 0.87 | STING1 (0.39) | STING1ADORA2A | |
| SCHEMBL21620380 | 0.85 | DRD3 (0.39) | STING1ADORA2A | |
| SCHEMBL21616395 | 0.85 | STING1 (0.47) | STING1ADORA2A | |
| SCHEMBL21616424 | 0.84 | STING1 (0.41) | STING1ADORA2A | |
| SCHEMBL19436528 | 0.81 | KMT2A (0.50) | KMT2A | |
| SCHEMBL19436567 | 0.81 | KMT2A (0.50) | KMT2A | |
| SCHEMBL21643845 | 0.80 | STING1 (0.42) | STING1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132493-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | FULGENT GENETICS INC (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132493-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | STING1, IRF3, MAVS | STING1 1/4885ADORA2A 604/4885KMT2A 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.